Upgrade
|
Wedbush analyst James… Wedbush analyst James Hardiman upgraded American Outdoor Brands to Outperform from Neutral. ShowHide Related Items >><< AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands jumps 7% to $17.00 after beat and raise quarter
- 12/15/20
- American Outdoor Brands reports Q2 e-commerce channel sales up 213.4%
- 12/15/20
- American Outdoor Brands reports Q2 gross margin 46.9%, up 690 bps
- 09/23/20
- American Outdoor Brands up over 2% after disclosing insider purchase by CEO, CFO
AOUT American Outdoor Brands - 12/16/20 Lake Street
- Lake Street ups American Outdoor Brands price target to $24 after Q2 report
- 11/18/20 CL King
- American Outdoor Brands initiated with a Buy at CL King
- 09/10/20 Spin-Off Research
- American Outdoor Brands upgraded to Buy from Hold at Spin-Off Research
- 09/04/20 Lake Street
- American Outdoor Brands price target raised to $23 from $21 at Lake Street
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands raises FY21 adj. EPS view to $1.49-$1.67 from 78c-89c
- 12/15/20
- American Outdoor Brands reports Q2 adjusted EPS 77c, consensus 25c
- 09/03/20
- American Outdoor Brands sees FY21 non-GAAP EPS 78c-89c, no estimates
- 09/03/20
- American Outdoor Brands reports Q1 non-GAAP EPS 36c, consensus (20c)
AOUT American Outdoor Brands - 12/16/20
- Fly Intel: Wall Street's top stories for Wednesday
- 12/16/20
- Fly Intel: Wall Street's top stories at midday
- 12/16/20
- Fly Intel: Pre-market Movers
- 12/15/20
- Fly Intel: After-Hours Movers
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands options imply 17.3% move in share price post-earnings
- 09/10/20
- Five new option listings and one option delisting on September 10th
|
On The Fly
| ShowHide Related Items >><< - 12/16/20
- Aphria, Tilray announce $3.9B combination
- 12/16/20
- Aphria, Tilray confirm merger agreement with implied equity value of C$5B
- 12/15/20
- Tilray up 8%, Aphria up 2% after merger speculation reported by Bloomberg
- 12/02/20
- Tilray enters cannabis extracts co-promotion agreement with Hormosan in Germany
- 12/15/20
- Sio Gene Therapies announces follow-up data from AXO-AAV-GM1 study
- 12/02/20
- Sio Gene Therapies reports first patient dosed in AXO-AAV-GM1 trial
- 11/19/20
- Sio Gene Therapies appoints Guangping Gao as Chief AAV Scientifc Advisor
- 11/13/20
- Sio Gene Therapies expects cash to sustain operations into 4Q21
- 12/16/20
- Starbucks sees Q1 U.S. comp sales down 5%-6%, China comp sales up 4%-5%
- 12/16/20
- Starbucks: FY21 EPS view remains intact as margin strength offets sales softness
- 12/16/20
- Starbucks saw slight sequential improvement in comp entering Q1
- 12/15/20
- Starbucks VP Angela Lis sells $465K in company shares
- 12/16/20
- Cuomo says NYS to receive 80K more Pfizer vaccine doses in the next days
- 12/16/20
- Five Star Senior Living residents to receive COVID-19 vaccinations
- 12/15/20
- Pfizer CEO sees vaccine from plants to any U.S. point of use within two days
- 12/14/20
- Pfizer, BioNTech announce additional data from Phase 1/2 trial of BNT162b2
- $175.06 /
-13.54 (-7.18%) - 12/16/20
- Penumbra falls -9.7%
- 12/16/20
- Penumbra falls -10.6%
- 12/15/20
- Penumbra recalls JET 7 Reperfusion Catheters with Xtra Flex technology
- 12/08/20
- Penumbra down 12%, off earlier lows after issuing response to short seller
- $137.00 /
-10.29 (-6.99%) - 12/15/20
- Moderna higher after FDA says vaccine is 'highly effective' and safe
- 12/15/20
- FDA calls Moderna Covid vaccine 'highly effective' ahead of panel meeting
- 12/15/20
- FDA says Moderna's Covid vaccine data meets expectations for emergency use
- 12/15/20
- FDA says Moderna's vaccine is safe, effective against Covid-19
- $1,763.12 /
-3.95 (-0.22%) - 12/16/20
- Apple TV app launching on new Chromecast with Google TV
- 12/16/20
- Qualcomm, Google extend pact for Snapdragon mobile platforms
- 12/14/20
- FTC seeking data from Facebook, other social media and streaming services
- 12/14/20
- Google services, including Gmail, suffering widespread outage
- $97.08 /
-22.02 (-18.49%) - 12/15/20
- Galapagos to assume development, manufacturing, other rights for Jyseleca
- 12/15/20
- Gilead will not pursue FDA approval of Jyseleca for RA
- 12/01/20
- Galapagos announces 1st dosing in Mangrove trial in GLPG2737 with ADPKD patient
- 11/30/20
- Galapagos presents results with GLPG1205 in IPF patients in Pinta trial
- 12/16/20
- Kite granted conditional marketing authorization for Tecartus from EC
- 12/10/20
- Gilead presents new data from ASCENT trial of Trodelvy
- $275.65 /
-0.195 (-0.07%) - 12/16/20
- Facebook says 'no choice but to show Apple's prompt'
- 12/16/20
- Facebook says Apple policy will hurt its diversified ads business
- 12/16/20
- Facebook says new Apple policy will hurt small businesses
- 12/15/20
- Facebook to allow political ads for Georgia runoff elections
- 12/16/20
- Brinker announces business update regarding impact from COVID-19
- 08/30/20
- Brinker rises 13.2%
- 08/28/20
- Brinker rises 9.3%
- 08/12/20
- Brinker reports Q4 comparable restaurant sales down 36.7%
- 11/27/20
- Aphria expands 510 Vape offerings across adult-use brand portfolio
- 11/24/20
- Cannabis stocks soar as Trump approves start of transition to Biden
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands jumps 7% to $17.00 after beat and raise quarter
- 12/15/20
- American Outdoor Brands reports Q2 e-commerce channel sales up 213.4%
- 12/15/20
- American Outdoor Brands reports Q2 gross margin 46.9%, up 690 bps
- 09/23/20
- American Outdoor Brands up over 2% after disclosing insider purchase by CEO, CFO
- 12/17/20 Canaccord
- Aphria downgraded to Hold from Speculative Buy at Canaccord
- 12/17/20 Stifel
- Tilray upgraded to Hold from Sell at Stifel
- 12/17/20 Stifel
- Aphria downgraded to Hold from Buy at Stifel
- 12/16/20 Alliance Global Partners
- Aphria price target raised to C$12 from C$9 at Alliance Global Partners
- 12/17/20 MKM Partners
- Brinker price target raised to $60 from $55 at MKM Partners
- 12/14/20 JPMorgan
- Brinker price target raised to $55 from $50 at JPMorgan
- 10/29/20 Loop Capital
- Brinker price target raised to $61 from $55 at Loop Capital
- 10/20/20 JPMorgan
- Brinker price target raised to $50 from $40 at JPMorgan
- $137.00 /
-10.29 (-6.99%) - 12/16/20
- Fly Intel: Top five analyst downgrades
- 12/16/20 KeyBanc
- Maravai Lifesciences initiated with an Overweight at KeyBanc
- 12/16/20 Morgan Stanley
- Morgan Stanley downgrades Moderna to Equal Weight, raises price target to $150
- 12/16/20 Morgan Stanley
- Moderna downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/16/20 RBC Capital
- Pfizer downgraded to Sector Perform from Outperform at RBC Capital
- 12/15/20 Jefferies
- Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
- 12/16/20 Stephens
- Starbucks pointed to softer U.S., stronger China than expected, says Stephens
- 12/10/20 Jefferies
- Starbucks price target raised to $115 from $105 at Jefferies
- 12/10/20 Morgan Stanley
- Starbucks price target raised to $106 from $98 at Morgan Stanley
- 12/10/20 RBC Capital
- Starbucks price target raised to $115 from $109 at RBC Capital
- $1,763.12 /
-3.95 (-0.22%) - 12/16/20 JPMorgan
- Alphabet price target raised to $2,050 from $1870 at JPMorgan
- 12/16/20 Morgan Stanley
- Fitbit downgraded to Underweight on pending deal completion at Morgan Stanley
- 12/14/20 BMO Capital
- BMO downgrades Disney after recent run, names new top media pick
- 12/07/20 Cowen
- Google potential action against IAC Desktop biz not major issue, says Cowen
- $1,757.18 /
-4.12 (-0.23%) - 11/27/20 Truist
- Amazon to claim 42c of every e-commerce dollar spent, says Truist
- $275.65 /
-0.195 (-0.07%) - 12/10/20 KeyBanc
- FTC antitrust suit against Facebook contained no major surprises, says KeyBanc
- 12/10/20 UBS
- Facebook's future deals may face more scrutiny, says UBS
- 11/27/20 MKM Partners
- Facebook, Google may also be interested in Slack, says MKM Partners
- 12/17/20 Morgan Stanley
- AT&T downgraded to Equal Weight on rising 5G risks at Morgan Stanley
- 12/16/20 Morgan Stanley
- Apple price target raised to $144 from $136 at Morgan Stanley
- 12/15/20 JPMorgan
- JPMorgan sees 20% upside for Apple shares in 2021
- 12/11/20 Citi
- Citi would look to add to Qualcomm positions, calls Apple report 'no biggie'
AOUT American Outdoor Brands - 12/16/20 Lake Street
- Lake Street ups American Outdoor Brands price target to $24 after Q2 report
- 11/18/20 CL King
- American Outdoor Brands initiated with a Buy at CL King
- 09/10/20 Spin-Off Research
- American Outdoor Brands upgraded to Buy from Hold at Spin-Off Research
- 09/04/20 Lake Street
- American Outdoor Brands price target raised to $23 from $21 at Lake Street
- $97.08 /
-22.02 (-18.49%) - 12/17/20 Maxim
- Galapagos price target lowered to $140 from $170 at Maxim
- 12/17/20 Oppenheimer
- Gilead price target lowered to $100 from $105 at Oppenheimer
- 12/17/20 Citi
- Galapagos price target lowered to EUR 113 from EUR 148 at Citi
- 12/17/20 Bryan Garnier
- Galapagos downgraded to Sell from Buy at Bryan Garnier
- 12/16/20 BMO Capital
- Gilead price target lowered to $62 from $64 at BMO Capital
- 12/16/20 Baird
- Gilead price target raised to $67 from $63 at Baird
- $175.06 /
-13.54 (-7.18%) - 12/16/20 Wells Fargo
- Penumbra price target lowered to $215 from $265 at Wells Fargo
- 12/16/20 Canaccord
- Penumbra price target lowered to $204 from $292 at Canaccord
- 12/16/20 Citi
- Citi keeps Buy rating on Penumbra, says recall 'clearning event'
- 11/09/20
- Tilray sees positive or break even adjusted EBITDA in Q4
- 11/09/20
- Tilray reports Q3 EPS (2c), consensus (21c)
- 08/26/20
- Vireo Health reports Q2 adjusted net loss $7.4M versus loss of $4.1M in Q219
- 08/10/20
- Tilray reports Q2 EPS (66c), consensus (27c)
- 11/13/20
- Sio Gene Therapies reports Q3 EPS (21c), consensus (29c)
- 12/16/20
- Starbucks backs FY21 adjusted EPS view $2.70-$2.90, consensus $2.82
- 12/16/20
- Starbucks sees Q1 adjusted EPS 50c-55c, consensus 56c
- 12/09/20
- Starbucks sees FY22 adjusted EPS growth at least 20%, consensus $3.28
- 12/09/20
- Starbucks backs FY21 adjusted EPS view $2.70-$2.90, consensus $2.81
- 10/27/20
- Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B
- 10/27/20
- Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B
- 10/27/20
- Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95
- 10/27/20
- Pfizer reports Q3 adjusted EPS 72c, consensus 71c
- $175.06 /
-13.54 (-7.18%) - 10/28/20
- Penumbra reports Q3 non-GAAP EPS 6c, consensus (8c)
- 08/03/20
- Penumbra reports Q2 EPS (34c), consensus (39c)
- $137.00 /
-10.29 (-6.99%) - 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- $1,757.18 /
-4.12 (-0.23%) - 10/29/20
- Alphabet CFO sees signs user behavior beginning to return to normalized level
- $1,763.12 /
-3.95 (-0.22%) - 10/29/20
- Alphabet reports Q3 Traffic Acquisition Costs $8.17B vs. $7.49B a year ago
- 10/29/20
- Alphabet reports Q3 Google Cloud revenue $3.44B vs. $2.38B a year ago
- 10/29/20
- Alphabet reports Q3 Google advertising revenue $37.1B vs. $33.8B a year ago
- 10/29/20
- Alphabet reports Q3 EPS $16.40, consensus $11.29
- $97.08 /
-22.02 (-18.49%) - 08/06/20
- Galapagos reports first half EPS EUR (2.55) vs. (1.76) last year
- 10/28/20
- Gilead sees core business gradually recovering in Q4 and into 1H21
- 10/28/20
- Gilead narrows FY20 adjusted EPS view to $6.25-$6.60 from $6.25-$7.65
- 10/28/20
- Gilead Sciences reports Q3 adjusted EPS $2.11, consensus $1.95
- 10/28/20
- Notable companies reporting after market close
- $275.65 /
-0.195 (-0.07%) - 10/29/20
- Facebook sees Q4 ad revenue growth rate higher than Q3
- 10/29/20
- Facebook reports Q3 EPS $2.71, consensus $1.91
- 10/29/20
- Notable companies reporting after market close
- 07/30/20
- Facebook reports Q2 EPS $1.80, consensus $1.39
- 12/16/20
- Brinker withdraws Q2 guidance in response to COVID-19
- 10/28/20
- Brinker sees Q2 ex-items EPS 40c-60c, consensus 44c
- 10/28/20
- Brinker reports Q3 ex-items EPS 28c, consensus (19c)
- 10/27/20
- Notable companies reporting before tomorrow's open
- 10/15/20
- Aphria reports Q1 EPS (C$0.02) vs. C$0.07 year ago
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands raises FY21 adj. EPS view to $1.49-$1.67 from 78c-89c
- 12/15/20
- American Outdoor Brands reports Q2 adjusted EPS 77c, consensus 25c
- 09/03/20
- American Outdoor Brands sees FY21 non-GAAP EPS 78c-89c, no estimates
- 09/03/20
- American Outdoor Brands reports Q1 non-GAAP EPS 36c, consensus (20c)
- 10/29/20
- Apple says Q4 results were ahead of expectations
- 10/29/20
- Apple reports Q4 Services revenue $14.55B vs. $12.51B last year
- 10/29/20
- Apple reports Q4 iPhone revenue $24.44B vs. $33.36B last year
- 10/29/20
- Apple reports Q4 EPS 73c, consensus 70c
|
On The Fly
|
Equity futures spent the… ShowHide Related Items >><< - 12/16/20
- Aphria, Tilray announce $3.9B combination
- 12/16/20
- Aphria, Tilray confirm merger agreement with implied equity value of C$5B
- 12/15/20
- Tilray up 8%, Aphria up 2% after merger speculation reported by Bloomberg
- 12/02/20
- Tilray enters cannabis extracts co-promotion agreement with Hormosan in Germany
- 12/15/20
- Sio Gene Therapies announces follow-up data from AXO-AAV-GM1 study
- 12/02/20
- Sio Gene Therapies reports first patient dosed in AXO-AAV-GM1 trial
- 11/19/20
- Sio Gene Therapies appoints Guangping Gao as Chief AAV Scientifc Advisor
- 11/13/20
- Sio Gene Therapies expects cash to sustain operations into 4Q21
- 12/16/20
- Starbucks sees Q1 U.S. comp sales down 5%-6%, China comp sales up 4%-5%
- 12/16/20
- Starbucks: FY21 EPS view remains intact as margin strength offets sales softness
- 12/16/20
- Starbucks saw slight sequential improvement in comp entering Q1
- 12/15/20
- Starbucks VP Angela Lis sells $465K in company shares
- 12/16/20
- Five Star Senior Living residents to receive COVID-19 vaccinations
- 12/15/20
- Pfizer CEO sees vaccine from plants to any U.S. point of use within two days
- 12/14/20
- Pfizer, BioNTech announce additional data from Phase 1/2 trial of BNT162b2
- 12/13/20
- Fly Intel: Top five weekend stock stories
- 12/16/20
- Penumbra falls -9.7%
- 12/16/20
- Penumbra falls -10.6%
- 12/15/20
- Penumbra recalls JET 7 Reperfusion Catheters with Xtra Flex technology
- 12/08/20
- Penumbra down 12%, off earlier lows after issuing response to short seller
- 12/15/20
- Moderna higher after FDA says vaccine is 'highly effective' and safe
- 12/15/20
- FDA calls Moderna Covid vaccine 'highly effective' ahead of panel meeting
- 12/15/20
- FDA says Moderna's Covid vaccine data meets expectations for emergency use
- 12/15/20
- FDA says Moderna's vaccine is safe, effective against Covid-19
- $97.06 /
-22.04 (-18.51%) - 12/15/20
- Galapagos to assume development, manufacturing, other rights for Jyseleca
- 12/15/20
- Gilead will not pursue FDA approval of Jyseleca for RA
- 12/01/20
- Galapagos announces 1st dosing in Mangrove trial in GLPG2737 with ADPKD patient
- 11/30/20
- Galapagos presents results with GLPG1205 in IPF patients in Pinta trial
- 12/16/20
- Kite granted conditional marketing authorization for Tecartus from EC
- 12/10/20
- Gilead presents new data from ASCENT trial of Trodelvy
- 12/16/20
- Brinker announces business update regarding impact from COVID-19
- 08/30/20
- Brinker rises 13.2%
- 08/28/20
- Brinker rises 9.3%
- 08/12/20
- Brinker reports Q4 comparable restaurant sales down 36.7%
- 11/27/20
- Aphria expands 510 Vape offerings across adult-use brand portfolio
- 11/24/20
- Cannabis stocks soar as Trump approves start of transition to Biden
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands jumps 7% to $17.00 after beat and raise quarter
- 12/15/20
- American Outdoor Brands reports Q2 e-commerce channel sales up 213.4%
- 12/15/20
- American Outdoor Brands reports Q2 gross margin 46.9%, up 690 bps
- 09/23/20
- American Outdoor Brands up over 2% after disclosing insider purchase by CEO, CFO
- 12/16/20 Roth Capital
- Roth Capital calls Tilray, Aphria tie-up 'sensible combination'
- 12/16/20 Cantor Fitzgerald
- Aphria, Tilray deal makes sense, says Cantor Fitzgerald
- 12/04/20 Alliance Global Partners
- Alliance Global sees low odds of MORE Act passing this congressional session
- 12/02/20 Alliance Global Partners
- Alliance Global Partners sees UN cannabis reclassification helping legalization
- 12/14/20 JPMorgan
- Brinker price target raised to $55 from $50 at JPMorgan
- 10/29/20 Loop Capital
- Brinker price target raised to $61 from $55 at Loop Capital
- 10/20/20 JPMorgan
- Brinker price target raised to $50 from $40 at JPMorgan
- 10/15/20 BMO Capital
- Brinker upgraded to Outperform from Market Perform at BMO Capital
- 12/16/20
- Fly Intel: Top five analyst downgrades
- 12/16/20 KeyBanc
- Maravai Lifesciences initiated with an Overweight at KeyBanc
- 12/16/20 Morgan Stanley
- Morgan Stanley downgrades Moderna to Equal Weight, raises price target to $150
- 12/16/20 Morgan Stanley
- Moderna downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/16/20 RBC Capital
- Pfizer downgraded to Sector Perform from Outperform at RBC Capital
- 12/15/20 Jefferies
- Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
- 12/10/20 Jefferies
- Starbucks price target raised to $115 from $105 at Jefferies
- 12/10/20 Morgan Stanley
- Starbucks price target raised to $106 from $98 at Morgan Stanley
- 12/10/20 RBC Capital
- Starbucks price target raised to $115 from $109 at RBC Capital
- 12/10/20 Oppenheimer
- Starbucks price target raised to $120 from $112 at Oppenheimer
AOUT American Outdoor Brands - 12/16/20 Lake Street
- Lake Street ups American Outdoor Brands price target to $24 after Q2 report
- 11/18/20 CL King
- American Outdoor Brands initiated with a Buy at CL King
- 09/10/20 Spin-Off Research
- American Outdoor Brands upgraded to Buy from Hold at Spin-Off Research
- 09/04/20 Lake Street
- American Outdoor Brands price target raised to $23 from $21 at Lake Street
- $97.06 /
-22.04 (-18.51%) - 12/16/20 Baird
- Gilead price target raised to $67 from $63 at Baird
- 11/23/20 UBS
- Galapagos price target lowered to EUR 116 from EUR 125 at UBS
- 11/19/20 Maxim
- Galapagos initiated with a Buy at Maxim
- 11/12/20 JPMorgan
- Galapagos price target lowered to EUR 120 from EUR 130 at JPMorgan
- 12/16/20 BMO Capital
- Gilead price target lowered to $62 from $64 at BMO Capital
- 12/16/20 Mizuho
- Gilead news removes overhang on shares, says Mizuho
- 12/15/20 Piper Sandler
- Gilead price target lowered to $80 from $84 at Piper Sandler
- 12/16/20 Wells Fargo
- Penumbra price target lowered to $215 from $265 at Wells Fargo
- 12/16/20 Canaccord
- Penumbra price target lowered to $204 from $292 at Canaccord
- 12/16/20 Citi
- Citi keeps Buy rating on Penumbra, says recall 'clearning event'
- 11/09/20
- Tilray sees positive or break even adjusted EBITDA in Q4
- 11/09/20
- Tilray reports Q3 EPS (2c), consensus (21c)
- 08/26/20
- Vireo Health reports Q2 adjusted net loss $7.4M versus loss of $4.1M in Q219
- 08/10/20
- Tilray reports Q2 EPS (66c), consensus (27c)
- 11/13/20
- Sio Gene Therapies reports Q3 EPS (21c), consensus (29c)
- 12/16/20
- Starbucks backs FY21 adjusted EPS view $2.70-$2.90, consensus $2.82
- 12/16/20
- Starbucks sees Q1 adjusted EPS 50c-55c, consensus 56c
- 12/09/20
- Starbucks sees FY22 adjusted EPS growth at least 20%, consensus $3.28
- 12/09/20
- Starbucks backs FY21 adjusted EPS view $2.70-$2.90, consensus $2.81
- 10/27/20
- Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B
- 10/27/20
- Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B
- 10/27/20
- Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95
- 10/27/20
- Pfizer reports Q3 adjusted EPS 72c, consensus 71c
- 10/28/20
- Penumbra reports Q3 non-GAAP EPS 6c, consensus (8c)
- 08/03/20
- Penumbra reports Q2 EPS (34c), consensus (39c)
- 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- $97.06 /
-22.04 (-18.51%) - 08/06/20
- Galapagos reports first half EPS EUR (2.55) vs. (1.76) last year
- 10/28/20
- Gilead sees core business gradually recovering in Q4 and into 1H21
- 10/28/20
- Gilead narrows FY20 adjusted EPS view to $6.25-$6.60 from $6.25-$7.65
- 10/28/20
- Gilead Sciences reports Q3 adjusted EPS $2.11, consensus $1.95
- 10/28/20
- Notable companies reporting after market close
- 12/16/20
- Brinker withdraws Q2 guidance in response to COVID-19
- 10/28/20
- Brinker sees Q2 ex-items EPS 40c-60c, consensus 44c
- 10/28/20
- Brinker reports Q3 ex-items EPS 28c, consensus (19c)
- 10/27/20
- Notable companies reporting before tomorrow's open
- 10/15/20
- Aphria reports Q1 EPS (C$0.02) vs. C$0.07 year ago
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands raises FY21 adj. EPS view to $1.49-$1.67 from 78c-89c
- 12/15/20
- American Outdoor Brands reports Q2 adjusted EPS 77c, consensus 25c
- 09/03/20
- American Outdoor Brands sees FY21 non-GAAP EPS 78c-89c, no estimates
- 09/03/20
- American Outdoor Brands reports Q1 non-GAAP EPS 36c, consensus (20c)
|
On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 12/15/20
- Tilray up 8%, Aphria up 2% after merger speculation reported by Bloomberg
- 12/02/20
- Tilray enters cannabis extracts co-promotion agreement with Hormosan in Germany
- 12/15/20
- Sio Gene Therapies announces follow-up data from AXO-AAV-GM1 study
- 12/02/20
- Sio Gene Therapies reports first patient dosed in AXO-AAV-GM1 trial
- 11/19/20
- Sio Gene Therapies appoints Guangping Gao as Chief AAV Scientifc Advisor
- 11/13/20
- Sio Gene Therapies expects cash to sustain operations into 4Q21
- $188.60 /
-0.995 (-0.52%) - 12/15/20
- Penumbra recalls JET 7 Reperfusion Catheters with Xtra Flex technology
- 12/08/20
- Penumbra down 12%, off earlier lows after issuing response to short seller
- 12/08/20
- Penumbra trading resumes
- 12/08/20
- Penumbra 'stands by the record' of JET 7 Xtra Flex
- 12/15/20
- Moderna higher after FDA says vaccine is 'highly effective' and safe
- 12/15/20
- FDA calls Moderna Covid vaccine 'highly effective' ahead of panel meeting
- 12/15/20
- FDA says Moderna's Covid vaccine data meets expectations for emergency use
- 12/15/20
- FDA says Moderna's vaccine is safe, effective against Covid-19
- 11/16/20
- iQIYI falls 5% to $26.50 after Q3 results, Q4 guidance
- 10/05/20
- iQIYI review didn't uncover any evidence to substantiate Wolfpack claims
- 10/05/20
- iQIYI: Internal Review complete, no evidence to substantiate Wolfpack claims
- 09/21/20
- iQIYI announces partnership with WWE
GLSI Greenwich LifeSciences - $53.34 /
+6.205 (+13.16%) - 12/15/20
- Greenwich LifeSciences Inc trading resumes
- 12/15/20
- Greenwich LifeSciences Inc trading halted, volatility trading pause
- 12/15/20
- Greenwich LifeSciences announces agreement with Westport Bio
- 12/11/20
- Greenwich LifeSciences presents data from GP2 Phase 3 trial
- 12/16/20
- Brinker announces business update regarding impact from COVID-19
- 08/30/20
- Brinker rises 13.2%
- 08/28/20
- Brinker rises 9.3%
- 08/12/20
- Brinker reports Q4 comparable restaurant sales down 36.7%
- 11/24/20
- Quest says average turnaround time for Covid tests now 2-3 days
- 11/23/20
- Quest Diagnostics announces lab services relationships with two hospitals
- 10/05/20
- Quest Diagnostics announces new collaboration with secure identity company Clear
- 09/30/20
- Quest Diagnostics launches three combined COVID-19 and respiratory virus tests
- 12/16/20
- Aphria, Tilray announce $3.9B combination
- 12/16/20
- Aphria, Tilray confirm merger agreement with implied equity value of C$5B
- 11/27/20
- Aphria expands 510 Vape offerings across adult-use brand portfolio
- 11/24/20
- Cannabis stocks soar as Trump approves start of transition to Biden
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands jumps 7% to $17.00 after beat and raise quarter
- 12/15/20
- American Outdoor Brands reports Q2 e-commerce channel sales up 213.4%
- 12/15/20
- American Outdoor Brands reports Q2 gross margin 46.9%, up 690 bps
- 09/23/20
- American Outdoor Brands up over 2% after disclosing insider purchase by CEO, CFO
- 12/16/20 Cantor Fitzgerald
- Aphria, Tilray deal makes sense, says Cantor Fitzgerald
- 12/04/20 Alliance Global Partners
- Alliance Global sees low odds of MORE Act passing this congressional session
- 12/02/20 Alliance Global Partners
- Alliance Global Partners sees UN cannabis reclassification helping legalization
- 11/06/20 CIBC
- Aphria price target raised to C$9 from C$8 at CIBC
- 11/16/20
- Fly Intel: Top five analyst downgrades
- 10/26/20 Mizuho
- Quest Diagnostics price target raised to $149 from $144 at Mizuho
- 10/21/20 Argus
- Quest Diagnostics upgraded to Buy from Hold at Argus
- 10/21/20 Argus
- Quest Diagnostics upgraded to Buy from Hold at Argus
- 10/16/20 Baird
- Baird 'pounding the table' on lab stocks after 'favorable' CMS update
AOUT American Outdoor Brands - 12/16/20 Lake Street
- Lake Street ups American Outdoor Brands price target to $24 after Q2 report
- 11/18/20 CL King
- American Outdoor Brands initiated with a Buy at CL King
- 09/10/20 Spin-Off Research
- American Outdoor Brands upgraded to Buy from Hold at Spin-Off Research
- 09/04/20 Lake Street
- American Outdoor Brands price target raised to $23 from $21 at Lake Street
- 12/14/20 JPMorgan
- Brinker price target raised to $55 from $50 at JPMorgan
- 10/29/20 Loop Capital
- Brinker price target raised to $61 from $55 at Loop Capital
- 10/20/20 JPMorgan
- Brinker price target raised to $50 from $40 at JPMorgan
- 10/15/20 BMO Capital
- Brinker upgraded to Outperform from Market Perform at BMO Capital
- 12/16/20 KeyBanc
- Maravai Lifesciences initiated with an Overweight at KeyBanc
- 12/16/20 Morgan Stanley
- Morgan Stanley downgrades Moderna to Equal Weight, raises price target to $150
- 12/16/20 Morgan Stanley
- Moderna downgraded to Equal Weight from Overweight at Morgan Stanley
- 12/15/20 Jefferies
- Jefferies downgrades Moderna to Hold after 'strong run'
- $188.60 /
-0.995 (-0.52%) - 12/16/20 Wells Fargo
- Penumbra price target lowered to $215 from $265 at Wells Fargo
- 12/16/20 Canaccord
- Penumbra price target lowered to $204 from $292 at Canaccord
- 12/16/20 Citi
- Citi keeps Buy rating on Penumbra, says recall 'clearning event'
- 12/16/20 BTIG
- Penumbra downgraded to Neutral from Buy at BTIG
- 11/03/20 Loop Capital
- Baidu price target raised to $150 from $130 at Loop Capital
- 08/14/20 CLSA
- iQIYI downgraded to Underperform from Outperform at CLSA
- 08/14/20 New Street
- iQIYI downgraded to Neutral from Buy at New Street
- 07/02/20 Loop Capital
- iQIYI price target raised to $23 from $20 at Loop Capital
GLSI Greenwich LifeSciences - $53.34 /
+6.205 (+13.16%) - 11/09/20
- Tilray sees positive or break even adjusted EBITDA in Q4
- 11/09/20
- Tilray reports Q3 EPS (2c), consensus (21c)
- 08/10/20
- Tilray reports Q2 EPS (66c), consensus (27c)
- 11/13/20
- Sio Gene Therapies reports Q3 EPS (21c), consensus (29c)
- $188.60 /
-0.995 (-0.52%) - 10/28/20
- Penumbra reports Q3 non-GAAP EPS 6c, consensus (8c)
- 08/03/20
- Penumbra reports Q2 EPS (34c), consensus (39c)
- 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- 11/16/20
- iQIYI sees Q4 revenue $1.07B-$1.14B, consensus $1.13B
- 11/16/20
- iQIYI reports Q3 EPS (24c), consensus (40c)
- 08/13/20
- iQIYI sees Q3 revenue $984.1M-$1.0B, consensus $1.07B
- 08/13/20
- iQIYI reports Q2 EPS (28c), consensus (49c)
- 12/16/20
- Brinker withdraws Q2 guidance in response to COVID-19
- 10/28/20
- Brinker sees Q2 ex-items EPS 40c-60c, consensus 44c
- 10/28/20
- Brinker reports Q3 ex-items EPS 28c, consensus (19c)
- 10/27/20
- Notable companies reporting before tomorrow's open
- 12/16/20
- Quest Diagnostics raises FY20 adj. EPS view to at least $10.75 from $9.00-$10.00
- 10/22/20
- Quest Diagnostics raises FY20 adj. EPS view to $9.00-$10.00 from $7.50-$9.00
- 10/22/20
- Quest Diagnostics reports Q3 adj. EPS $4.31, consensus $3.73
- 10/21/20
- Notable companies reporting before tomorrow's open
- 10/15/20
- Aphria reports Q1 EPS (C$0.02) vs. C$0.07 year ago
- 08/26/20
- Vireo Health reports Q2 adjusted net loss $7.4M versus loss of $4.1M in Q219
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands raises FY21 adj. EPS view to $1.49-$1.67 from 78c-89c
- 12/15/20
- American Outdoor Brands reports Q2 adjusted EPS 77c, consensus 25c
- 09/03/20
- American Outdoor Brands sees FY21 non-GAAP EPS 78c-89c, no estimates
- 09/03/20
- American Outdoor Brands reports Q1 non-GAAP EPS 36c, consensus (20c)
|
Recommendations
|
Lake Street analyst Mark… Lake Street analyst Mark Smith raised the firm's price target on American Outdoor Brands to $24 from $23 and keeps a Buy rating on the shares after the company reported Q2 results that were "well above" his estimates and consensus forecasts. Smith thinks improved outdoor participation rates and "healthy" FBI background check data support strong firearm and accessory demand and he also thinks the investments the company has made in e-commerce will allow it to continue to grow in a strong market, he tells investors. ShowHide Related Items >><< AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands jumps 7% to $17.00 after beat and raise quarter
- 12/15/20
- American Outdoor Brands reports Q2 e-commerce channel sales up 213.4%
- 12/15/20
- American Outdoor Brands reports Q2 gross margin 46.9%, up 690 bps
- 09/23/20
- American Outdoor Brands up over 2% after disclosing insider purchase by CEO, CFO
AOUT American Outdoor Brands - 11/18/20 CL King
- American Outdoor Brands initiated with a Buy at CL King
- 09/10/20 Spin-Off Research
- American Outdoor Brands upgraded to Buy from Hold at Spin-Off Research
- 09/04/20 Lake Street
- American Outdoor Brands price target raised to $23 from $21 at Lake Street
- 09/01/20 Lake Street
- Smith & Wesson Brands price target lowered to $25 from $28 at Lake Street
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands raises FY21 adj. EPS view to $1.49-$1.67 from 78c-89c
- 12/15/20
- American Outdoor Brands reports Q2 adjusted EPS 77c, consensus 25c
- 09/03/20
- American Outdoor Brands sees FY21 non-GAAP EPS 78c-89c, no estimates
- 09/03/20
- American Outdoor Brands reports Q1 non-GAAP EPS 36c, consensus (20c)
AOUT American Outdoor Brands - 12/15/20
- Fly Intel: After-Hours Movers
- 09/23/20
- Fly Intel: After-Hours Movers
- 09/03/20
- Fly Intel: After-Hours Movers
AOUT American Outdoor Brands - 12/15/20
- American Outdoor Brands options imply 17.3% move in share price post-earnings
- 09/10/20
- Five new option listings and one option delisting on September 10th
|